Express News | Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Mizuho Securities Maintains Incyte(INCY.US) With Hold Rating, Cuts Target Price to $70
Mizuho Securities Keeps Their Hold Rating on Incyte (INCY)
Incyte to Present at Upcoming Investor Conference
Incyte's Promising Drug Pipeline and Strong Financial Performance Reinforce Buy Rating
9 Analysts Have This To Say About Incyte
TD Cowen Lowers Price Target on Incyte to $86 From $88
Incyte Price Target Raised to $59.00/Share From $58.00 by Wells Fargo
Wells Fargo Maintains Equal-Weight on Incyte, Raises Price Target to $59
Incyte Is Maintained at Sector Perform by RBC Capital
Morgan Stanley Adjusts Incyte's Price Target to $68 From $65
Incyte Analyst Ratings
RBC Raises Price Target on Incyte to $67 From $64, Keeps Sector Perform Rating
Analysts Offer Insights on Healthcare Companies: Option Care Health (OPCH), Incyte (INCY) and Verona Pharma (VRNA)
Incyte's Growth Prospects Hindered by Jakafi's Exclusivity Loss and Strategic Limitations
Express News | Incyte : Stifel Cuts Target Price to $75 From $77
Incyte's Q1 2025 Earnings: Strong Growth and Optimism
BofA Securities Maintains Incyte(INCY.US) With Buy Rating, Raises Target Price to $89
TD Cowen Maintains Incyte(INCY.US) With Buy Rating, Cuts Target Price to $86